Sio Gene Therapies (NASDAQ:SIOX) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Sio Gene Therapies (NASDAQ:SIOX) released its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.17, MarketWatch Earnings reports.

Sio Gene Therapies stock opened at $2.41 on Thursday. Sio Gene Therapies has a 52 week low of $1.86 and a 52 week high of $5.74. The stock’s fifty day simple moving average is $2.43. The firm has a market cap of $113.87 million and a PE ratio of -0.82.

SIOX has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Sio Gene Therapies in a research report on Wednesday, May 5th. Zacks Investment Research lowered Sio Gene Therapies from a “buy” rating to a “hold” rating in a research report on Saturday, April 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Sio Gene Therapies in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $10.92.

In other news, CEO Pavan Cheruvu bought 100,000 shares of the stock in a transaction on Tuesday, March 23rd. The stock was acquired at an average price of $2.48 per share, with a total value of $248,000.00. Following the acquisition, the chief executive officer now directly owns 180,426 shares in the company, valued at $447,456.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.20% of the stock is owned by corporate insiders.

Sio Gene Therapies Company Profile

Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.

Read More: What is a balanced fund?

Earnings History for Sio Gene Therapies (NASDAQ:SIOX)

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with's FREE daily email newsletter.